<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Imugene Ltd — News on 6ix</title>
<link>https://6ix.com/company/imugene-ltd</link>
<description>Latest news and press releases for Imugene Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 11:05:03 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/imugene-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836669b78dffbe2df15e01a.webp</url>
<title>Imugene Ltd</title>
<link>https://6ix.com/company/imugene-ltd</link>
</image>
<item>
<title>Prospectus</title>
<link>https://6ix.com/company/imugene-ltd/news/prospectus-25</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/prospectus-25</guid>
<pubDate>Tue, 17 Mar 2026 11:05:03 GMT</pubDate>
<description>Prospectus</description>
</item>
<item>
<title>$20M placement and SPP, convertible notes amended</title>
<link>https://6ix.com/company/imugene-ltd/news/dollar20m-placement-and-spp-convertible-notes-amended</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/dollar20m-placement-and-spp-convertible-notes-amended</guid>
<pubDate>Wed, 11 Mar 2026 06:56:03 GMT</pubDate>
<description>$20M placement and SPP, convertible notes amended</description>
</item>
<item>
<title>100% and 80% ORRs in Subset Indications in azer-cel study</title>
<link>https://6ix.com/company/imugene-ltd/news/100percent-and-80percent-orrs-in-subset-indications-in-azer-cel-study</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/100percent-and-80percent-orrs-in-subset-indications-in-azer-cel-study</guid>
<pubDate>Tue, 10 Mar 2026 03:24:04 GMT</pubDate>
<description>100% and 80% ORRs in Subset Indications in azer-cel study</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/imugene-ltd/news/trading-halt-466</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/trading-halt-466</guid>
<pubDate>Tue, 10 Mar 2026 02:33:05 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/imugene-ltd/news/half-yearly-report-and-accounts-220</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/half-yearly-report-and-accounts-220</guid>
<pubDate>Wed, 25 Feb 2026 06:58:09 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/imugene-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-43</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-43</guid>
<pubDate>Fri, 30 Jan 2026 03:51:09 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>FDA Supports Strategy Toward Registration for Azer-cel</title>
<link>https://6ix.com/company/imugene-ltd/news/fda-supports-strategy-toward-registration-for-azer-cel</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/fda-supports-strategy-toward-registration-for-azer-cel</guid>
<pubDate>Mon, 08 Dec 2025 03:10:09 GMT</pubDate>
<description>FDA Supports Strategy Toward Registration for Azer-cel</description>
</item>
<item>
<title>Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours</title>
<link>https://6ix.com/company/imugene-ltd/news/imugene-jw-therapeutics-announce-collaboration-050000714</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/imugene-jw-therapeutics-announce-collaboration-050000714</guid>
<pubDate>Fri, 28 Nov 2025 05:00:00 GMT</pubDate>
<description>Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) and JW's Carteyva®—a CD19-directed autologous CAR-T cell therapy—for patients with advanced solid tumors.</description>
</item>
<item>
<title>Strategic Collaboration with JW Therapeutics</title>
<link>https://6ix.com/company/imugene-ltd/news/strategic-collaboration-with-jw-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/strategic-collaboration-with-jw-therapeutics</guid>
<pubDate>Thu, 27 Nov 2025 03:28:15 GMT</pubDate>
<description>Strategic Collaboration with JW Therapeutics</description>
</item>
<item>
<title>S&P DJI Announces September 2025 Quarterly Rebalance</title>
<link>https://6ix.com/company/imugene-ltd/news/sandp-dji-announces-september-2025-quarterly-rebalance-79</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/sandp-dji-announces-september-2025-quarterly-rebalance-79</guid>
<pubDate>Fri, 05 Sep 2025 11:28:14 GMT</pubDate>
<description>S&P DJI Announces September 2025 Quarterly Rebalance</description>
</item>
<item>
<title>Final Share Purchase Plan Allotment</title>
<link>https://6ix.com/company/imugene-ltd/news/final-share-purchase-plan-allotment</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/final-share-purchase-plan-allotment</guid>
<pubDate>Thu, 28 Aug 2025 09:10:10 GMT</pubDate>
<description>Final Share Purchase Plan Allotment</description>
</item>
<item>
<title>Appendix 4E and Annual Report</title>
<link>https://6ix.com/company/imugene-ltd/news/appendix-4e-and-annual-report-65</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/appendix-4e-and-annual-report-65</guid>
<pubDate>Tue, 26 Aug 2025 03:41:29 GMT</pubDate>
<description>Appendix 4E and Annual Report</description>
</item>
<item>
<title>Imugene Capital Raising Presentation</title>
<link>https://6ix.com/company/imugene-ltd/news/imugene-capital-raising-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/imugene-capital-raising-presentation</guid>
<pubDate>Wed, 16 Jul 2025 05:01:04 GMT</pubDate>
<description>Imugene Capital Raising Presentation</description>
</item>
<item>
<title>Imugene Completes $22.5M Placement and c.$15M SPP</title>
<link>https://6ix.com/company/imugene-ltd/news/imugene-completes-dollar225m-placement-and-cdollar15m-spp</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/imugene-completes-dollar225m-placement-and-cdollar15m-spp</guid>
<pubDate>Wed, 16 Jul 2025 04:57:03 GMT</pubDate>
<description>Imugene Completes $22.5M Placement and c.$15M SPP</description>
</item>
<item>
<title>Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL</title>
<link>https://6ix.com/company/imugene-ltd/news/imugene-announces-outstanding-response-rates-from-the-phase-1b-trial-of-the-azer-cel-allogeneic-car-t-in-3l-dlbcl</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/imugene-announces-outstanding-response-rates-from-the-phase-1b-trial-of-the-azer-cel-allogeneic-car-t-in-3l-dlbcl</guid>
<pubDate>Mon, 14 Jul 2025 04:43:00 GMT</pubDate>
<description>Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).</description>
</item>
<item>
<title>Two Additional Complete Responses in azer-cel Ph1b trial</title>
<link>https://6ix.com/company/imugene-ltd/news/two-additional-complete-responses-in-azer-cel-ph1b-trial</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/two-additional-complete-responses-in-azer-cel-ph1b-trial</guid>
<pubDate>Mon, 14 Jul 2025 02:55:11 GMT</pubDate>
<description>Two Additional Complete Responses in azer-cel Ph1b trial</description>
</item>
<item>
<title>Notice of Extraordinary General Meeting/Proxy Form</title>
<link>https://6ix.com/company/imugene-ltd/news/notice-of-extraordinary-general-meetingproxy-form-3</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/notice-of-extraordinary-general-meetingproxy-form-3</guid>
<pubDate>Tue, 27 May 2025 07:08:08 GMT</pubDate>
<description>Notice of Extraordinary General Meeting/Proxy Form</description>
</item>
<item>
<title>Azer-cel Granted FDA Fast Track Designation in Blood Cancer</title>
<link>https://6ix.com/company/imugene-ltd/news/azer-cel-granted-fda-fast-track-designation-in-blood-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/azer-cel-granted-fda-fast-track-designation-in-blood-cancer</guid>
<pubDate>Wed, 19 Mar 2025 02:23:33 GMT</pubDate>
<description>Azer-cel Granted FDA Fast Track Designation in Blood Cancer</description>
</item>
<item>
<title>S&P DJI Announces March 2025 Quarterly Rebalance</title>
<link>https://6ix.com/company/imugene-ltd/news/sandp-dji-announces-march-2025-quarterly-rebalance-90</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/sandp-dji-announces-march-2025-quarterly-rebalance-90</guid>
<pubDate>Fri, 07 Mar 2025 11:22:14 GMT</pubDate>
<description>S&P DJI Announces March 2025 Quarterly Rebalance</description>
</item>
<item>
<title>Imugene Granted India Patent for Oncolytic Virotherapy CF33</title>
<link>https://6ix.com/company/imugene-ltd/news/imugene-granted-india-patent-for-oncolytic-virotherapy-cf33</link>
<guid isPermaLink="true">https://6ix.com/company/imugene-ltd/news/imugene-granted-india-patent-for-oncolytic-virotherapy-cf33</guid>
<pubDate>Thu, 27 Feb 2025 03:19:30 GMT</pubDate>
<description>Imugene Granted India Patent for Oncolytic Virotherapy CF33</description>
</item>
</channel>
</rss>